Market Cap 2.35B
Revenue (ttm) 6.40B
Net Income (ttm) 864.00M
EPS (ttm) N/A
PE Ratio 2.53
Forward PE 2.43
Profit Margin 13.49%
Debt to Equity Ratio 12.14
Volume 3,563,700
Avg Vol 3,690,074
Day's Range N/A - N/A
Shares Out 259.97M
Stochastic %K 34%
Beta 0.63
Analysts Sell
Price Target $13.00

Company Profile

Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 551 430 6900
Address:
30 Hudson Street, Floor 33, Jersey City, United States
FrankieSmilez
FrankieSmilez Oct. 16 at 5:44 PM
$INVO $IVF $PGNY $NIVF $OGN IVF related stocks for WH update: PGNY (Progyny, Inc.) IVF (INVO Fertility, Inc.) NIVF (NewGenIvf Group Limited) COO (The Cooper Companies, Inc.) VITLF (Vitrolife AB) MRK (Merck KGaA) OGN (Organon & Co.) NTRA (Natera, Inc.)
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Oct. 15 at 2:38 AM
$OGN took some today
0 · Reply
_CircuitBreaker
_CircuitBreaker Oct. 9 at 11:44 PM
Keep a close watch on CMCT! $RKDA $DSGX $OGN $SLS 3
0 · Reply
tarprocapital
tarprocapital Oct. 9 at 8:57 PM
$OGN what's happening? Under 10 again!
0 · Reply
handmedown1
handmedown1 Oct. 8 at 8:51 PM
$OGN wow
0 · Reply
BasisTrader
BasisTrader Oct. 5 at 3:27 PM
$OGN Pharmaceutical spin-off. Testing key support. Volume pattern shows distribution. Pipeline valuation debate.
0 · Reply
secondtimearound
secondtimearound Oct. 1 at 3:38 PM
$OGN got a gap to fill above
0 · Reply
frankster
frankster Sep. 30 at 9:52 PM
$BMY $MRK $OGN $PFE here’s our first biggest catalyst! These drug companies negotiating the a deal with the administration on price discounts and direct to consumer is a major step and on top of it getting a long break from paying tariffs. They’re all easily undervalued 30-40% imo.
0 · Reply
frankster
frankster Sep. 30 at 11:54 AM
$BMY lost 25% value this year! as if AI not going to revolutionize cancer research and provide efficiency for these major biotech players! it’s comical how money has left this sector. I think it’ll come back with vengeance in a short period once few catalysts hit the wire. $PFE $MRK $OGN
0 · Reply
SweepCastApp
SweepCastApp Sep. 26 at 12:37 PM
$OGN: TRADE CALL contracts spotted 60 @ 4.57, Strike 7.5, Exp 1/21/2028, Premium $27,420, Sentiment NEUTRAL
0 · Reply
Latest News on OGN
Organon: Valuation Discount Offset By Structural Headwinds

Aug 12, 2025, 2:22 PM EDT - 2 months ago

Organon: Valuation Discount Offset By Structural Headwinds


Organon & Co. (OGN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 1:10 PM EDT - 2 months ago

Organon & Co. (OGN) Q2 2025 Earnings Call Transcript


Organon: A Look Beyond The Dividend Cut

Jun 18, 2025, 1:02 AM EDT - 4 months ago

Organon: A Look Beyond The Dividend Cut


FrankieSmilez
FrankieSmilez Oct. 16 at 5:44 PM
$INVO $IVF $PGNY $NIVF $OGN IVF related stocks for WH update: PGNY (Progyny, Inc.) IVF (INVO Fertility, Inc.) NIVF (NewGenIvf Group Limited) COO (The Cooper Companies, Inc.) VITLF (Vitrolife AB) MRK (Merck KGaA) OGN (Organon & Co.) NTRA (Natera, Inc.)
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Oct. 15 at 2:38 AM
$OGN took some today
0 · Reply
_CircuitBreaker
_CircuitBreaker Oct. 9 at 11:44 PM
Keep a close watch on CMCT! $RKDA $DSGX $OGN $SLS 3
0 · Reply
tarprocapital
tarprocapital Oct. 9 at 8:57 PM
$OGN what's happening? Under 10 again!
0 · Reply
handmedown1
handmedown1 Oct. 8 at 8:51 PM
$OGN wow
0 · Reply
BasisTrader
BasisTrader Oct. 5 at 3:27 PM
$OGN Pharmaceutical spin-off. Testing key support. Volume pattern shows distribution. Pipeline valuation debate.
0 · Reply
secondtimearound
secondtimearound Oct. 1 at 3:38 PM
$OGN got a gap to fill above
0 · Reply
frankster
frankster Sep. 30 at 9:52 PM
$BMY $MRK $OGN $PFE here’s our first biggest catalyst! These drug companies negotiating the a deal with the administration on price discounts and direct to consumer is a major step and on top of it getting a long break from paying tariffs. They’re all easily undervalued 30-40% imo.
0 · Reply
frankster
frankster Sep. 30 at 11:54 AM
$BMY lost 25% value this year! as if AI not going to revolutionize cancer research and provide efficiency for these major biotech players! it’s comical how money has left this sector. I think it’ll come back with vengeance in a short period once few catalysts hit the wire. $PFE $MRK $OGN
0 · Reply
SweepCastApp
SweepCastApp Sep. 26 at 12:37 PM
$OGN: TRADE CALL contracts spotted 60 @ 4.57, Strike 7.5, Exp 1/21/2028, Premium $27,420, Sentiment NEUTRAL
0 · Reply
mdes
mdes Sep. 24 at 4:04 PM
$LYB $OGN $WEN $UPS $DOW still no mercy here .. sucks holding these that don't give even trading bounces anymore
0 · Reply
mdes
mdes Sep. 21 at 9:15 PM
$LYB $OGN $WEN $UPS worst hit stocks over last 12 months, even rate cuts not helping (may be pfe but it showed some life in between)
1 · Reply
MrNotSoNice
MrNotSoNice Sep. 15 at 10:44 PM
$OGN Can this company grow revenue and pay down debt? 🤔
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Sep. 14 at 1:10 PM
The attachment compiles certain valuation related data points on 9 mature commercial-stage bios (3 in oncology & 6 in non-oncology). For the more mature bios in this peer group, we consider enterprise value related multiples the best predictor of value potential (since all 9 are long past traditional M&A exit timelines). $OGN appears to be the most leveraged. Should they be able to service the debt (not considered in EPS) then... We understand $PTCT first meaningful FDA approval came in 2017 so they are the youngest in this peer group. They are the only bio of the 9 still not profitable. $BMRN is hovering near 52-week lows yet still appears to trade at revenue multiples consistent with others in this peer group. $ACAD & $ALKS have almost identical multiples. ACAD just got a major IP extension. This is not investment advice as we do not follow the non-oncology bios in this peer group in any detail. We'd otherwise appreciate genuine feedback. Are we missing a data point to consider?
1 · Reply
Obliviously
Obliviously Sep. 12 at 5:06 AM
$OGN Momentum looks favorable. If higher volume confirms, this could be a real bounce, not just a short-term tick.
0 · Reply
Winning_calls
Winning_calls Sep. 8 at 3:36 PM
$OGN 😉😉
0 · Reply
Winning_calls
Winning_calls Sep. 8 at 3:19 AM
$OGN pick me up @ $10.34
0 · Reply
frankster
frankster Sep. 7 at 1:57 AM
$OGN it's dirt cheap but clearly market doesn't care for now. perhaps rate cuts and some good news will finally lit some fire under this. 20-30 stock in few yrs imo. got 10,000 shares and not looking at it for awhile.
0 · Reply
JClem_Stocks
JClem_Stocks Sep. 5 at 4:20 PM
$OGN I’ll keep adding if it goes under $10 again…. Easy $15-$20 per share. Already undervalued, but with latest advancements, should see market catch up to it…
0 · Reply
biotechworld
biotechworld Sep. 3 at 8:07 PM
$OGN started position. Looks good 👍
0 · Reply
Chickenstick1
Chickenstick1 Sep. 3 at 7:26 PM
0 · Reply
handmedown1
handmedown1 Sep. 3 at 7:01 PM
$OGN $BMY someone will buy this. Pe of 1
1 · Reply